New antiretrovirals: What's in it for Southern Africa?

Southern African Journal of HIV Medicine

Volumn , Issue 32, 2008, Pages 44-50

  Venter, W D Francois ^a   Osih, Regina ^a   Andrews, Steve ^b,c   Conradie, Francesca ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VICRIVIROC;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYOPATHY; NAUSEA; SALVAGE THERAPY; SOUTH AFRICA; TERATOGENICITY;

EID: 59849083350     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cahn P, Sued O. Raltegravir: a new antiretroviral class for salvage therapy. Lancet 2007; 369 (9569): 1235-1236.
2. Correl T, Klibanov OM. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection, Pharmacotherapy 2008; 28(1): 90-101.
3. Dolin R. A new class of anti-HIV therapy and new challenges. N Engl J Med 2008; 359(14): 1509-1511.
4. Hirschel B, Perneger T. No patient left behind - better treatments for resistant HIV infection. Lancet 2007; 370: 3-5.
5. Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation Pls, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 2008; 57(1): 1-10
6. Jayaweera DT, Espinoza L, Castro J. Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors. Expert Opin Pharmacother 2008; 9(17): 3083-3094.
7. Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev 2008; 10(3): 131-142.
8. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infecton. Clin Ther 2000; 30(7): 1228-1250.
9. Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis 2008; 198(1): 51-58.
10. Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDs 2008; 22(6): 459-471.
11. Omar S, Cahn P. Raltegravir: opening the road for integrase inhibitors in clinical practice. Future HIV Therapy 2008; 2(3): 217-227.
12. Orman JS, Perry CM. Tipranavir: a review of its use in the management of HIV infection. Drugs 2008; 68(10): 1435-1463.
13. Rotty J, Hoy J. New therapeutic agents in the management of HIV: an overview of darunavir for clinicians. Sex Health 2008; 5(3): 235-241.
14. van Roey J, von Schoen-Angerer T, Ford N, Calmy A. How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. Drug Discov Today 2008; 13(13-14): 601-605.
15. Venter WDF, Wilson D, Conradie F, Variava E. Antiretroviral drug resistance: A clinician's guide in South Africa. Southern African Journal of HIV Medicine 2006; Issue 22 (March), pp. 30-37.